In this episode of the Spotlight On, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN).
In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues. The conversation then pivots to what Cybin sees as the main issues with psilocybin: its long duration of effect, long period before onset action, and the variability in effects from person to person.
After discussing the potential issues, Doug Drysdale discusses Cybin’s new molecule, CYB-003, which is a modified version of psilocybin. While CYB-003 is still in the preclinical phases, Doug says that it mitigates the negative features of psilocybin, when used in a therapy setting, while keeping the benefits. Cybin hopes to launch their new psilocybin in clinical trials early next year.
Can psychedelics treat mental health disorders?
Cybin believes yes, and they plan on using their molecule, CYB-003 to prove this!
#Cybin #MagicMushrooms #CybnStock
Have you heard about our new community?
We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.